Jak 2 V617F Common Mutation Pcr Blood

Practo

Tests

Gurgaon

Gurgaon Sector 14

Jak 2 V617F Common Mutation Pcr Blood

Book lab tests at home

  • Compare prices
  • • On-time home sample pick up
  • • On-time e-reports
NABL and CAP
310 tests booked
Free home sample pickupNext slot tuesday at 12:30 AM
Total: ₹5300
Book home sample
NABL and CAP
5 tests booked
Home sample pickupNext slot tuesday at 2:00 AM
Total: ₹6500
Book home sample
62 tests booked
Home sample pickupNext slot tuesday at 2:30 AM
Total: ₹6000
Book home sample
23 tests booked
Free home sample pickupNext slot tuesday at 12:30 AM
Total: ₹5900
Book home sample
Other labs
STATUS
You have no active orders!
mini-tick
Personalised health checkup
Get master health check-ups at home.
Starting at just ₹ 999 Book Now
Home Sample pickup

Test Information

Diagnose Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Idiopathic Myelofibrosis (MF). The Janus kinase 2 gene (JAK2) codes for a tyrosine kinase (JAK2) that is associated with the cytoplasmic portion of a variety of transmembrane cytokine and growth factor receptors important for signal transduction in hematopoietic cells. Signaling via JAK2 activation causes phosphorylation of downstream signal transducers and activators of transcription (STAT) proteins (eg, STAT5) ultimately leading to cell growth and differentiation. BCR-ABL1-negative myeloproliferative neoplasms (MPN) frequently harbor an acquired single nucleotide mutation in JAK2 characterized as c.G1849T; p. Val617Phe (V617F). This mutation is identified overall in approximately two-thirds of all MPN,(1-3) but the prevalence varies by MPN subtype. The JAK2 V617F is present in 95% to 98% of polycythemia vera, 50% to 60% of primary myelofibrosis, and 50% to 60% of essential thrombocythemia. It has also been described infrequently in other myeloid neoplasms, including chronic myelomonocytic leukemia and myelodysplastic syndrome.(4) This mutation is not seen in chronic myelogenous leukemia (CML) or in reactive conditions with elevated blood counts. Detection of the JAK2 V617F is useful to help establish the diagnosis of MPN. However, a negative JAK2 V617F result does not indicate absence of a MPN. Other important molecular markers in BCR-ABL1-negative MPN include CALR exon 9 mutation (20%-30% of PMF and ET) and MPL exon 10 mutation (5%-10% of PMF and 3%-5% of ET).(5-9) Mutations in JAK2, CALR, and MPL are essentially mutually exclusive.

Also known as: JAK 2 V617F Common Mutation.

Have More Questions?

  • Why is this test required?
  • What are the test preparations?
  • What is the general cost of this test?
Know more